AARD vs VOR
AARD: Aardvark Therapeutics is a clinical-stage biopharmaceutical company developing its lead small molecule candidate, ARD-101, for metabolic and rare disease indications. VOR: Vor Biopharma is a clinical-stage biopharmaceutical company developing advanced cell therapy and gene therapy solutions for blood disorders and cancers.
Side-by-side fundamentals
| Metric | AARD | VOR | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $6.60 | $19.44 | |
| Market cap as of 2026-08-02 | $144M | $1.1B | |
| PEG as of 2026-08-02 | -1.23 | -0.00 | AARD lower |
| ROE as of 2026-08-02 | -61.7% | -142.1% | AARD higher |
| ROA as of 2026-08-02 | -56.3% | -261.2% | AARD higher |
| Debt / equity as of 2026-08-02 | 0.00 | 0.00 | Tie |
| Beta as of 2026-08-02 | 1.88 | 1.60 | |
| 1-year return as of 2026-07-31 close | -45.0% | -55.8% | AARD higher |
Fundamentals: market data, as of 2026-08-02. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.